Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEK + GPI-0100
- Development stage
- Unknown
- Lead developer
- Avantogen
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
PEK + GPI-0100 is an investigational therapeutic cancer vaccine composed of a recombinant fusion protein (PEK) and a semi-synthetic saponin adjuvant (GPI-0100). The PEK component is a fusion of the Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins, linked to a signal peptide (P1) and an endoplasmic reticulum (ER) retention signal (KDEL). This specific molecular architecture is designed to direct the viral antigens to the ER, thereby enhancing their processing and presentation via the MHC class I pathway to stimulate a robust CD8+ T-cell response. GPI-0100 serves as an adjuvant to further augment cellular (Th1) and humoral immune responses while minimizing the toxicity typically associated with traditional saponins like QS-21. The vaccine has been primarily evaluated in Phase 1 clinical trials for the treatment of HPV16-positive cervical intraepithelial neoplasia (CIN), including low-grade and high-grade squamous intraepithelial lesions (LSIL/HSIL).
- Other names
- P1-E6-E7-KDEL + GPI-0100PEK fusion protein vaccineHPV16 E6/E7 fusion protein vaccine
02
Targets
HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on PEK + GPI-0100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEK + GPI-0100.